{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:10:22Z","timestamp":1773277822119,"version":"3.50.1"},"reference-count":24,"publisher":"The Endocrine Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9,1]]},"DOI":"10.1210\/jc.2012-1026","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T01:58:50Z","timestamp":1339466330000},"page":"3270-3276","source":"Crossref","is-referenced-by-count":13,"title":["Phenotypes of Interferon-\u03b1-Induced Thyroid Dysfunction among Patients Treated for Hepatitis C Are Associated with Pretreatment Serum TSH and Female Sex"],"prefix":"10.1210","volume":"97","author":[{"given":"Jennifer S.","family":"Mammen","sequence":"first","affiliation":[{"name":"Department of Medicine (J.S.M., P.W.L.), Division of Endocrinology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon R.","family":"Ghazarian","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (S.R.G.), Baltimore, Maryland 21224"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Pulkstenis","sequence":"additional","affiliation":[{"name":"Human Genome Sciences, Inc. (E.P.), Rockville, Maryland 20850"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Mani","family":"Subramanian","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc. (G.M.S.), Foster City, California 94404"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antony","family":"Rosen","sequence":"additional","affiliation":[{"name":"Department of Medicine (A.R.), Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul W.","family":"Ladenson","sequence":"additional","affiliation":[{"name":"Department of Medicine (J.S.M., P.W.L.), Division of Endocrinology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041113421936500_B1","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/0016-5085(92)90348-3","article-title":"Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa.","volume":"102","author":"Lisker-Melman","year":"1992","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2019041113421936500_B2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2265.2010.03785.x","article-title":"Thyroid dysfunction in a UK hepatitis C population treated with interferon-alpha and ribavirin combination therapy.","volume":"73","author":"Costelloe","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041113421936500_B3","doi-asserted-by":"crossref","first-page":"934","DOI":"10.4158\/EP10036.OR","article-title":"Thyroid function outcomes after pegylated interferon-\u03b1 and ribavirin therapy for chronic hepatitis C.","volume":"16","author":"Tran","year":"2010","journal-title":"Endocr Pract"},{"key":"key\n\t\t\t\t2019041113421936500_B4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3748\/wjg.15.328","article-title":"Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C.","volume":"15","author":"Gelu-Simeon","year":"2009","journal-title":"World J Gastroenterol"},{"key":"key\n\t\t\t\t2019041113421936500_B5","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/j.1440-1746.2008.05690.x","article-title":"Interferon-induced thyroid dysfunction in chronic hepatitis C.","volume":"24","author":"Jamil","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t2019041113421936500_B6","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1440-1746.2009.05874.x","article-title":"Development of thyroid diseases in the treatment of chronic hepatitis C with \u03b1-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis.","volume":"24","author":"Tran","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t2019041113421936500_B7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1665-2681(19)31891-5","article-title":"Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis.","volume":"7","author":"Rodr\u00edguez-Torres","year":"2008","journal-title":"Ann Hepatol"},{"key":"key\n\t\t\t\t2019041113421936500_B8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0003-4266(06)72609-9","article-title":"Thyroid disorders during interferon \u03b1 therapy in 625 patients with chronic hepatitis C: a prospective cohort study.","volume":"67","author":"Kabbaj","year":"2006","journal-title":"Ann Endocrinol (Paris)"},{"issue":"1 Pt 2","key":"key\n\t\t\t\t2019041113421936500_B9","first-page":"319","article-title":"Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: Incidence, associated factors and prognosis.","volume":"21","author":"Kee","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t2019041113421936500_B10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0399-8320(05)80778-X","article-title":"Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C.","volume":"29","author":"Moncoucy","year":"2005","journal-title":"Gastroenterol Clin Biol"},{"key":"key\n\t\t\t\t2019041113421936500_B11","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1001\/archinte.164.21.2371","article-title":"Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study.","volume":"164","author":"Bini","year":"2004","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019041113421936500_B12","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1046\/j.1365-2796.2002.00974.x","article-title":"Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: No association with either interferon dosage or efficacy of therapy.","volume":"251","author":"Dalgard","year":"2002","journal-title":"J Intern Med"},{"key":"key\n\t\t\t\t2019041113421936500_B13","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E","article-title":"Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy.","volume":"43","author":"Ioannou","year":"2000","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041113421936500_B14","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0168-8278(99)80131-7","article-title":"HLA antigens in patients with interferon-\u03b1-induced autoimmune thyroid disorders in chronic hepatitis C.","volume":"30","author":"Kakizaki","year":"1999","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t2019041113421936500_B15","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/hep.510260127","article-title":"Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy.","volume":"26","author":"Deutsch","year":"1997","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t2019041113421936500_B16","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cyto.2010.01.009","article-title":"Interferon-\u03b1, -\u03b2, and -\u03b3 induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-\u03b3 agonists.","volume":"50","author":"Antonelli","year":"2010","journal-title":"Cytokine"},{"key":"key\n\t\t\t\t2019041113421936500_B17","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.4049\/jimmunol.1002631","article-title":"IFN-\u03b1 mediates the development of autoimmunity both by direct tissue toxicity and through immune cell recruitment mechanisms.","volume":"186","author":"Akeno","year":"2011","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t2019041113421936500_B18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.beem.2009.07.004","article-title":"Interferon induced thyroiditis.","volume":"23","author":"Tomer","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113421936500_B19","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1053\/j.gastro.2010.06.066","article-title":"Albinterferon alfa-2b was not inferior to pegylated interferon-\u03b1 in a randomized trial of patients with chronic hepatitis C virus genotype 1.","volume":"139","author":"Zeuzem","year":"2010","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2019041113421936500_B20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/jcem.87.2.8182","article-title":"Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).","volume":"87","author":"Hollowell","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113421936500_B21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1001\/archinte.1987.00370020041032","article-title":"Postpartum lymphocytic thyroiditis. Prevalence, clinical course, and long-term follow-up.","volume":"147","author":"Nikolai","year":"1987","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019041113421936500_B22","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1210\/jc.2007-0287","article-title":"National Health and Nutrition Examination Survey III thyroid-stimulating hormone (TSH)-thyroperoxidase antibody relationships demonstrate that TSH upper reference limits may be skewed by occult thyroid dysfunction.","volume":"92","author":"Spencer","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113421936500_B23","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1210\/jc.2007-1499","article-title":"Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: Implications for the prevalence of subclinical hypothyroidism.","volume":"92","author":"Surks","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113421936500_B24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1478-3231.2011.02703.x","article-title":"2011 european association of the study of the liver hepatitis C virus clinical practice guidelines.","volume":"32","author":"Calvaruso","year":"2012","journal-title":"Liver Int"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/97\/9\/3270\/9048474\/jcem3270.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T04:23:11Z","timestamp":1714018991000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/97\/9\/3270\/2537035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,1]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2012-1026","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717950689.793456007","asserted-by":"object"}]},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,1]]}}}